On the bravest frontier in human health, scientists are using bacteria from the digestive system to create novel medicines for a huge range of ailments including Parkinson’s, cancer and autism. The results could transform lives and deliver massive returns for early investors
Milltrust’s VC partner Cerracap was a day 1 investor into Viome. We are proud to have helped pioneered this fascinating technology which uses AI to analyse millions of data points derived from the contents of our gut.
Categories: News
Tags: Cerracap Healthcare Science Technology viome